Weight loss variability with SGLT2 inhibitors and GLP‐1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial

(2018) Richard E. Pratley et al.   DIABETES OBESITY & METABOLISM

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study

(2018) Philip Ambery et al.   LANCET

Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial

(2018) Bernhard Ludvik et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial

(2018) Patrick M O'Neil et al.   LANCET

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

(2018) Juan Pablo Frias et al.   LANCET

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial

(2017) Bo Ahrén et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

(2017) Christopher Sorli et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

(2017) Vanita R Aroda et al.   Lancet Diabetes & Endocrinology

Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis

(2016) Rune V. Overgaard et al.   CLINICAL PHARMACOKINETICS

Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis

(2016) Jay S. Skyler et al.   DIABETES

Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders

(2016) Sarah Steven et al.   DIABETES CARE

Exposure-response analyses of liraglutide 3.0 mg for weight management

(2016) J. P. H. Wilding et al.   DIABETES OBESITY & METABOLISM

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Persistent metabolic adaptation 6 years after “The Biggest Loser” competition

(2016) Erin Fothergill et al.   Obesity

How Strongly Does Appetite Counter Weight Loss? Quantification of the Feedback Control of Human Energy Intake

(2016) David Polidori et al.   Obesity

Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers

(2016) Ken Fujioka et al.   Obesity

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial

(2016) Juan P Frías et al.   Lancet Diabetes & Endocrinology

Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study

(2016) John Wilding et al.   Diabetes Therapy

Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study

(2016) John Wilding et al.   Diabetes Therapy

Validation of an inexpensive and accurate mathematical method to measure long-term changes in free-living energy intake

(2015) Arjun Sanghvi et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus

(2015) Eef Hoeben et al.   CLINICAL PHARMACOKINETICS

Dapagliflozin Improves Glycemic Control and Reduces Body Weight as Add-on Therapy to Metformin Plus Sulfonylurea: A 24-Week Randomized, Double-Blind Clinical Trial

(2015) Stephan Matthaei et al.   DIABETES CARE

Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From aDiabetes CareEditors’ Expert Forum

(2015) William T. Cefalu et al.   DIABETES CARE

Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition

(2015) S. P. Rajeev et al.   DIABETES OBESITY & METABOLISM

Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study

(2015) Mojca Jensterle et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes

(2015) Melanie J. Davies et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor

(2015) Daniel Antonio de Luis et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion

(2015) Caroline Bonner et al.   NATURE MEDICINE

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

(2015) Xavier Pi-Sunyer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predicting successful long-term weight loss from short-term weight-loss outcomes: new insights from a dynamic energy balance model (the POUNDS Lost study)

(2014) Diana M Thomas et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans

(2014) L. van Bloemendaal et al.   DIABETES

Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin

(2014) Julio Rosenstock et al.   DIABETES CARE

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

(2014) Hans-Ulrich Häring et al.   DIABETES CARE

Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

(2014) Carol Wysham et al.   DIABETES CARE

The adaptive metabolic response to exercise-induced weight loss influences both energy expenditure and energy intake

(2014) M Hopkins et al.   EUROPEAN JOURNAL OF CLINICAL NUTRITION

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats

(2014) Masanori Yokono et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Association of Bariatric Surgery With Long-term Remission of Type 2 Diabetes and With Microvascular and Macrovascular Complications

(2014) Lars Sjöström et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production

(2014) Aurora Merovci et al.   JOURNAL OF CLINICAL INVESTIGATION

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

(2014) Ele Ferrannini et al.   JOURNAL OF CLINICAL INVESTIGATION

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

(2014) Kathleen M Dungan et al.   LANCET

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study

(2014) Richard E Pratley et al.   Lancet Diabetes & Endocrinology

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial

(2014) Martin Ridderstråle et al.   Lancet Diabetes & Endocrinology

Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin

(2013) John P.H. Wilding   ANNALS OF INTERNAL MEDICINE

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

(2013) Clifford J Bailey et al.   BMC Medicine

Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)

(2013) J. Rosenstock et al.   DIABETES CARE

Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

(2013) Serge A. Jabbour et al.   DIABETES CARE

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study

(2013) T A Wadden et al.   INTERNATIONAL JOURNAL OF OBESITY

Adherence and Success in Long-Term Weight Loss Diets: The Dietary Intervention Randomized Controlled Trial (DIRECT)

(2013) Ilana Greenberg et al.   JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

(2013) William T Cefalu et al.   LANCET

Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus

(2013) Harold E. Bays et al.   Obesity

FTO Genotype and 2-Year Change in Body Composition and Fat Distribution in Response to Weight-Loss Diets: The POUNDS LOST Trial

(2012) X. Zhang et al.   DIABETES

Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes

(2012) J. Rosenstock et al.   DIABETES CARE

The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial

(2012) J. Rosenstock et al.   DIABETES CARE

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

(2012) K. Stenlöf et al.   DIABETES OBESITY & METABOLISM

Metabolic Slowing with Massive Weight Loss despite Preservation of Fat-Free Mass

(2012) Darcy L. Johannsen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Glucagon-Like Peptide 1 (GLP-1) Analogue, Exendin-4, Decreases the Rewarding Value of Food: A New Role for Mesolimbic GLP-1 Receptors

(2012) S. L. Dickson et al.   JOURNAL OF NEUROSCIENCE

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

(2012) John B Buse et al.   LANCET

Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes

(2012) Philip R. Schauer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet-Induced Obese (DIO) Rats

(2012) James J. Devenny et al.   Obesity

Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models

(2012) Yin Liang et al.   PLoS One

SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function

(2011) Michael J. Jurczak et al.   DIABETES

Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes

(2011) J. Dushay et al.   DIABETES CARE

Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial

(2011) M. A. Nauck et al.   DIABETES CARE

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial

(2011) K. Strojek et al.   DIABETES OBESITY & METABOLISM

Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol

(2011) E. L. Lim et al.   DIABETOLOGIA

Effect of Exenatide on Splanchnic and Peripheral Glucose Metabolism in Type 2 Diabetic Subjects

(2011) E. Cersosimo et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes

(2011) Thomas Blevins et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Dosing Rationale for Liraglutide in Type 2 Diabetes Mellitus: A Pharmacometric Assessment

(2011) Steen H. Ingwersen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Quantification of the effect of energy imbalance on bodyweight

(2011) Kevin D Hall et al.   LANCET

fMRI reactivity to high-calorie food pictures predicts short- and long-term outcome in a weight-loss program

(2011) Donna L. Murdaugh et al.   NEUROIMAGE

Long-Term Persistence of Hormonal Adaptations to Weight Loss

(2011) Priya Sumithran et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial

(2010) E. Ferrannini et al.   DIABETES CARE

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

(2010) J. B. Buse et al.   DIABETES CARE

Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes

(2010) Olivia J. Phung   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

(2010) Clifford J Bailey et al.   LANCET

Differences in attention to food and food intake between overweight/obese and normal-weight females under conditions of hunger and satiety

(2009) Ilse M.T. Nijs et al.   APPETITE

Familial Renal Glucosuria and SGLT2: From a Mendelian Trait to a Therapeutic Target

(2009) R. Santer et al.   Clinical Journal of the American Society of Nephrology

Association of Type 2 Diabetes Candidate Polymorphisms in KCNQ1 With Incretin and Insulin Secretion

(2009) K. Mussig et al.   DIABETES

A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion

(2009) S. A. Schäfer et al.   DIABETOLOGIA

Homeostatic and Hedonic Signals Interact in the Regulation of Food Intake

(2009) Michael Lutter et al.   JOURNAL OF NUTRITION

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

One-year Weight Losses in the Look AHEAD Study: Factors Associated With Success

(2009) Thomas A. Wadden et al.   Obesity

Hunger is the best spice: An fMRI study of the effects of attention, hunger and calorie content on food reward processing in the amygdala and orbitofrontal cortex

(2008) Nicolette Siep et al.   BEHAVIOURAL BRAIN RESEARCH

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET

The incretin system and its role in type 2 diabetes mellitus

(2008) J HOLST et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Resistance Training Conserves Fat-free Mass and Resting Energy Expenditure Following Weight Loss

(2008) Gary R. Hunter et al.   Obesity